Literature DB >> 35928853

Novel Macrocyclic 1,3,4-Oxadiazoles as CFTR Modulators for Treating Cystic Fibrosis.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35928853      PMCID： PMC9345374          DOI： 10.1021/acsmedchemlett.2c00288

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Small-molecule drugs for cystic fibrosis: Where are we now?

Authors:  Onofrio Laselva; Lorenzo Guerra; Stefano Castellani; Maria Favia; Sante Di Gioia; Massimo Conese
Journal:  Pulm Pharmacol Ther       Date:  2021-11-15       Impact factor: 3.410

Review 2.  Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.

Authors:  Jérémy Dana; Dominique Debray; Aurélie Beaufrère; Sophie Hillaire; Monique Fabre; Caroline Reinhold; Thomas F Baumert; Laureline Berteloot; Valérie Vilgrain
Journal:  J Hepatol       Date:  2021-10-20       Impact factor: 25.083

Review 3.  Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges: Adult Cystic Fibrosis Series.

Authors:  Patrick Maisonneuve; Albert B Lowenfels
Journal:  Chest       Date:  2021-09-15       Impact factor: 9.410

Review 4.  Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.

Authors:  Nicholas J Antos; Adrienne P Savant
Journal:  Pediatr Pulmonol       Date:  2021-05-25

Review 5.  Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies.

Authors:  Jessica E Caterini; Felix Ratjen; Alan R Barker; Craig A Williams; Kate Rendall; Jane E Schneiderman; Greg D Wells
Journal:  J Cyst Fibros       Date:  2021-12-24       Impact factor: 5.482

Review 6.  Cardiovascular complications in cystic fibrosis: A review of the literature.

Authors:  T Spencer Poore; Jennifer L Taylor-Cousar; Edith T Zemanick
Journal:  J Cyst Fibros       Date:  2021-06-14       Impact factor: 5.482
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.